Although the impact of KRAS mutations on radiosensitivity and MET is not clear, it has been shown that KRAS can influence and rewire the metabolic state of cancer cells and, therefore, could contribute to the different sensitivities to MET (39). The gene discussed is KRAS; the disease is cancer.